SCHEMBL20254635

SCHEMBL20254635

COc1c(C(C)C#N)cc(Cl)c(C)c1-c1cccnc1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PIK3CD O00329 8/20 0.41
▸ HTT P42858 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ MAPK1 P28482 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.37
▸ ACLY P53396 2/20 0.36
▸ CYP11B1 P15538 3/20 0.35
▸ CYP11B2 P19099 3/20 0.35
▸ CYP17A1 P05093 2/20 0.35
▸ CYP19A1 P11511 2/20 0.35
▸ CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688933 1.00 KDM4E (0.41) KDM4EMAPTPIK3CDHTTHSD17B10
SCHEMBL29688628 0.86 POLB (0.39) KDM4EMAPTPIK3CDHTTMAPK1
SCHEMBL20240836 0.86 POLB (0.39) KDM4EMAPTPIK3CDHTTMAPK1
SCHEMBL20240859 0.85 CYP11B1 (0.39) KDM4EMAPTPIK3CDHTTMAPK1
SCHEMBL30590299 0.85 CYP11B1 (0.39) KDM4EMAPTPIK3CDHTTMAPK1
SCHEMBL29688422 0.85 CYP11B1 (0.39) KDM4EMAPTPIK3CDHTTMAPK1
SCHEMBL20243515 0.81 AKR1C3 (0.44) PIK3CDACLYCYP11B1CYP11B2
SCHEMBL29688594 0.81 AKR1C3 (0.44) PIK3CDACLYCYP11B1CYP11B2
SCHEMBL20240823 0.80 PIK3CD (0.37) KDM4EMAPTPIK3CDHTTMAPK1
SCHEMBL28747455 0.77 PIK3CD (0.38) PIK3CDHTTMAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11725012-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2023-08-15 — — US disclosed
US-11725012-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2023-08-15 — — US disclosed
US-11725012-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2023-08-15 — — US disclosed
CN-114805366-A Imidazo [1,5-A ] pyrazine derivatives as PI3K delta inhibitors 百济神州有限公司 2022-07-29 — — CN disclosed
CN-110267959-B Imidazo [1,5-A ] pyrazine derivatives as PI3K delta inhibitors 百济神州有限公司 2022-05-27 — — CN disclosed
US-20220098202-A1 IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS BEONE MEDICINES I GMBH (CH) 2022-03-31 — — US disclosed
US-20220098202-A1 IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS BEONE MEDICINES I GMBH (CH) 2022-03-31 — — US disclosed
US-11136323-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2021-10-05 — — US disclosed
US-11136323-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2021-10-05 — — US disclosed
WO-2018103688-A1 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS BEIGENE, LTD. (KY) 2018-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220098202-A1 IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS PIK3CD, PIK3R5, PIK3CA KDM4E 3469/4885MAPT 3882/4885PIK3CD 1/4885
US-11136323-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors PIK3CD, PIK3R5, PIK3CA KDM4E 3721/4885MAPT 4070/4885PIK3CD 1/4885
US-11725012-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors PIK3CD, PIK3R5, PIK3CA KDM4E 3583/4885MAPT 3924/4885PIK3CD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback